CARsgen
is a China-based biotechnology company that develops and commercializes T-cell therapeutics for the treatment of cancer... Read moreCARsgen
is a China-based biotechnology company that develops and commercializes T-cell therapeutics for the treatment of cancer... Read more
News
Mar 27, 2025
Benzinga
CARsgen: CARsgen's R&D Progress Should Be A Key Watchpoint For Investors
Mar 19, 2025
PR Newswire
Press Release: CARsgen : CARsgen Announced 2024 Annual Results
Mar 03, 2025
PR Newswire
Press Release: CARsgen : CARsgen's Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA
Feb 28, 2025
PR Newswire
Press Release: CARsgen : CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune Disease
Feb 26, 2025
Marketscreener
CARsgen: CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China
Feb 11, 2025
Pharmabiz
CARsgen: CARsgen's first enrolled subject in the THANKu Plus platformbased allogeneic CART trial achieves sCR at week 4
Jan 21, 2025
Pharmabiz
CARsgen: CARsgen's allogeneic CD38 CART therapy administers first dose in an investigatorinitiated trial
Dec 31, 2024
centralcharts
Press Release: CARsgen : CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T Therapy
Dec 31, 2024
Pharmabiz
CARsgen: CARsgen Therapeutics announces positive results from China GC/GEJ pivotal phase II trial of Claudin18.2 CART
Nov 06, 2024
PR Newswire
Press Release: CARsgen : CARsgen to Present Zevor-cel, CT071 and CT0590 at ASH 2024 Annual Congress
